Deck the halls with res­ig­na­tions: Lian­Bio CEO, CFO out; CRISPR Ther­a­peu­tics CMO to leave in Jan­u­ary

→ On Dec. 16, Yizhe Wang turned in his res­ig­na­tion as CEO of Lian­Bio, while board mem­ber and Per­cep­tive chief in­vest­ment of­fi­cer Adam Stone will grab the reins on an in­ter­im ba­sis. The C-suite over­haul con­tin­ued on Tues­day when fi­nance chief Yi Lar­son al­so re­signed, trig­ger­ing an­oth­er in­ter­im ap­point­ment as head of glob­al fi­nance Mag­gie Gu han­dles CFO re­spon­si­bil­i­ties. Per­cep­tive’s Chi­na play is fac­ing an un­cer­tain fu­ture de­spite its rea­son­ably strong cash po­si­tion. Kevin Tang’s shell com­pa­ny Con­cen­tra Bio­sciences made an un­so­licit­ed of­fer to buy Lian­Bio that has since been re­buffed. Lian­Bio has hint­ed at pro­vid­ing more de­tails about its strate­gic re­view in Q1 af­ter end­ing the li­cens­ing agree­ment with part­ner Bris­tol My­ers Squibb for Camzyos in Chi­na and oth­er Asian coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER